BriaCell (BCTX) Therapeutics announced its acceptance into Memorial Sloan Kettering Cancer Center’s Therapeutics Accelerator 2025 Cohort program. This project aims to accelerate the clinical development of Bria-OTS+, BriaCell’s next generation personalized off-the-shelf immunotherapy, for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. As one of the world’s foremost cancer research and treatment institutions, MSK has more than 135 years of leadership in patient care, education and discovery. Through the MSK Therapeutics Accelerator Cohort program, BriaCell will explore access to MSK’s expertise and institutional resources, including GMP manufacturing services, Investigational New Drug Application preparation and submission and regulatory strategy support to expedite Bria-OTS+ development.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCTX:
- BriaCell Announces Share Consolidation to Maintain Nasdaq Compliance
- BriaCell Expands Phase 3 Breast Cancer Study with UCLA Health Partnership
- BriaCell adds UCLA Health as site in Phase 3 breast cancer study
- BriaCell Secures New Zealand Patent for Cancer Immunotherapy
- BriaCell awarded New Zealand patent for its whole cell technology